Safety and Feasability of High-Pressure/High-Dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin in Colorectal Peritoneal Surface Malignacies

Safety and Feasability of High-Pressure/High-Dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin in Colorectal Peritoneal Surface Malignacies: A Comparative Analysis

Dr. med. Fabian Kockelmann

BSc Valentina Romdhane

Prof. Dr. med. Jürgen Zieren

Prof. Dr. med. Urs Pabst-Giger (Projektleiter)

Prof. Dr. med. PhD Mehdi Ouaissi

Data collection completed

Departement of Surgery, Klinikum Dortmund, Germany

Witten/Herdecke University, Witten, Germany

Retrospective analysis of a prospective database of patients undergoing PIPAC with oxaliplatin for end-stage peritoneal surface malignancies at a single center. Group 1 low pressure/low dose PIPAC Group 2 high pressure/high dose PIPAC.

Outcome and feasibility of HP/HD-PIPAC

AT-ROVL (Association Tourangelle de la Rechereche en Oncologie Val de Loire)